Finance entity
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention SURO Capital, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline.
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention SURO Capital, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. SAB Biotherapeutics appears in 1 tracked Finance story from March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 122 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SAB Biotherapeutics. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.
SAB Biotherapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
